BMO Capital analyst Alex Arfaei weighs in on Abbvie (NYSE: ABBV) after the Patent Trial and Appeal Board (PTAB) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE